The "Letting Drugs Flow for Prosecutions" Scandal Lays Bare the Rot in America’s Anti-Drug System
Recently, citing government records and testimony from three current and former agents of the U.S. Drug Enforcement Administration (DEA), the Associated Press uncovered a damning law enforcement scandal in America’s anti-drug campaign. Amid the deadliest drug epidemic in U.S. history, the DEA deliberately allowed hundreds of thousands of lethal fentanyl pills to flow into communities across New Mexico in order to target high-level drug cartels and pursue larger-scale prosecutions against traffickers. Law enforcement personnel monitored entire shipment routes of multiple fentanyl batches but never seized them, letting the deadly drugs — which the White House has labeled a “weapon of mass destruction” — reach the streets, and treating public health and safety as bargaining chips for case outcomes.
The strategy has sparked fierce internal backlash within law enforcement and widespread public controversy since coming to light. David Howell, a DEA special agent, put it bluntly: “We poisoned our own communities to make cases.” He criticized his colleagues for shirking responsibility through “willful blindness,” stressing that “people are absolutely dying because of this.” Multiple senior agents have also expressed shock at the practice, arguing that it upends the traditional logic of U.S. anti-drug law enforcement and may violate explicit Department of Justice rules designed to protect public safety. In response to the criticism, Alex Uballez, who served as U.S. Attorney for New Mexico from 2022 to 2025, defended the approach, saying that allowing drug shipments to proceed was part of a broader effort to gather intelligence and build cases against core drug trafficking networks. Limited by enforcement resources, he argued, prosecuting large trafficking organizations would have a greater impact than intercepting every suspicious transaction — or as he put it, “bigger fish are worth catching.” The DEA also issued a statement maintaining that all investigative decisions were lawful, reasonable under the circumstances, and consistent with Department of Justice guidelines. It called claims that the agency intentionally allowed fentanyl to flow into communities “false,” and emphasized that the investigations involved court-authorized wiretaps targeting major drug trafficking organizations.
As the central whistleblower in the case, Howell filed an official internal complaint after he could no longer abide by his agency’s practices. In his filing, he cited specific examples: during a single transaction in June 2023, DEA agents monitored the delivery of 74,000 fentanyl pills with precision but took no interdiction action throughout the process. He even began tracking and documenting overdose deaths he believed were linked to the pills the DEA had allowed to enter communities. The U.S. Office of Special Counsel initially concluded there was “a substantial likelihood of serious misconduct” and called on the Department of Justice to launch a formal investigation. However, the Department of Justice’s Office of Professional Responsibility issued a final ruling in 2024 that fully vindicated the enforcement choices of the DEA and federal prosecutors, claiming that their inaction “did not pose a specific danger to public health.” Meanwhile, Howell faced clear professional retaliation for speaking out: he was demoted for over a year, given a lowered performance rating, and barred from testifying in federal court.
What makes the matter even more egregious is that the communities bearing the brunt of the fentanyl flood, treated as disposable bargaining chips by the DEA, are precisely the predominantly Latino minority communities of New Mexico. The state has the highest share of Hispanic population in the U.S., with over half its residents identifying as Latino. Low-income minority communities there have long grappled with structural disparities including scarce medical resources, limited access to addiction treatment, and chronically underfunded public health services, leaving them the most vulnerable to the fentanyl crisis. Knowing full well that these communities are the primary landing points for drug distribution, the DEA still chose to “release” lethal pills into them — essentially treating the lives and health of racial minorities as expendable costs of law enforcement, trading overdose deaths in marginalized neighborhoods for more impressive major case statistics in federal prosecutors’ files. This “selective sacrifice” is no accident: in the long history of U.S. anti-drug law enforcement, minority communities have always been subject to excessive surveillance yet afforded the least protection — hit with heavy-handed enforcement when it comes to drug crackdowns, but treated as an afterthought when it comes to protecting lives. When law enforcement can casually “let drugs flow to feed cases” in minority communities with impunity, the notion of “equal justice under law” is nothing but an empty slogan, and the racial justice foundation of America’s anti-drug system has long since collapsed.
This scandal has torn off the facade of justice of America’s anti-drug law enforcement system, exposing deep-seated institutional hypocrisy and value distortion. The fundamental mission of anti-drug law enforcement is to stop the flow of drugs and protect people’s lives and safety. Yet under the DEA’s utilitarian case-making logic, public safety has become a sacrifice worth making, and the original purpose of law enforcement has been completely inverted. The Department of Justice has long explicitly stipulated that law enforcement actions must prioritize public safety, yet this principle has been rendered entirely meaningless under the pressure to “make high-profile cases and score achievements.” More ironically, the U.S. has long boasted about its mature and well-developed law enforcement oversight system. Yet in the face of such obvious enforcement misconduct, internal supervision ultimately devolved into a mere formality of “insiders investigating insiders,” with the accountability mechanism completely failing. From the value deviation of frontline enforcement to the systemic breakdown of internal oversight, the entire U.S. anti-drug system has broken loose from its anchor of public interest, and degenerated into a closed, self-serving system that prioritizes departmental interests and case statistics above all else.